Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

New classes of antitubercular drugs, diarylquinolines and nitroimidazoles, have been associated with improved outcomes in the treatment of drug-resistant tuberculosis, but that success is threatened by emerging drug resistance. We report a case of bedaquiline and delamanid resistance in a 55-year-old woman in South Africa with extensively drug-resistant tuberculosis and known HIV.

Related collections

Most cited references 9

Record: found
Abstract: found
Article: found

Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis

Francesca Conradie, Tatevik R. Bagdasaryan, Sergey Borisov … (2022)

0 comments Cited 139 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.

Guido V Bloemberg, Peter Keller, David Stucki … (2015)

Treatment of multidrug-resistant Mycobacterium tuberculosis is a challenge. This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid.

0 comments Cited 133 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis … (2022)

0 comments Cited 107 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (nlm-ta): Emerg Infect Dis

Journal ID (iso-abbrev): Emerg Infect Dis

Journal ID (publisher-id): EID

Title: Emerging Infectious Diseases

Publisher: Centers for Disease Control and Prevention

ISSN (Print): 1080-6040

ISSN (Electronic): 1080-6059

Publication date (Print): May 2023

Volume: 29

Issue: 5

Pages: 1081-1084

Affiliations

[1]Guys and St Thomas' NHS Foundation Trust, London, UK (J. Millard);

[2]Wellcome Trust Liverpool Glasgow Centre for Global Health Research, Liverpool, UK (J. Millard);

[3]University of Liverpool, Liverpool (J. Millard);

[4]Africa Health Research Institute, Durban, South Africa (J. Millard, C. Nimmo);

[5]Imperial College Healthcare, London (S. Rimmer);

[6]Francis Crick Institute, London (C. Nimmo);

[7]University College London, London (C. Nimmo);

[8]Columbia University Medical Center, New York, New York, USA (M. O’Donnell);

[9]CAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Durban (M. O’Donnell)

Author notes

Address for correspondence: James Millard, Dept of Infectious Diseases, St Thomas' Hospital, Westminster Bridge Rd, London, SE1 7EH, UK; email: jmillard@ 123456liverpool.ac.uk

Article

Publisher ID: 22-1716

DOI: 10.3201/eid2905.221716

PMC ID: 10124645

PubMed ID: 37081529

SO-VID: 2bade289-e694-4f6e-a85a-96b9b3abf001

License:

Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.

Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB

Read this article at

Abstract

Related collections

UCL: UN SDG 03 Good Health and Well-Being

Most cited references 9

Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

Author and article information

Journal

Affiliations

Author notes

Article

History

Categories

Comments

Comment on this article

Similar content 334

Cited by 5

Most referenced authors 130